Malaysia eyes outsourcing gold through financial fog

By Nick Taylor

- Last updated on GMT

Related tags: Pharmacology

The Malaysian Biotechnology Corporation (BiotechCorp) is continuing to forge allegiances with Indian companies in an attempt to become a biotech and outsourcing hub.

BiotechCorp, a Malaysian development agency, recently undertook its first international activities of 2009, meeting with representatives of Indian industry in Hyderabad & Chennai.

Malaysia has launched a range of incentives in an attempt to attract biotechs and outsourcing companies to the nation, including 100 per cent income tax exemption for 10 years commencing from the first year the company derives profit.

The current centerpiece of its efforts to attract outsourcing is the decision by Malladi Drugs, a manufacturer of active pharmaceutical ingredients, to select Malaysia as the site for its expansion into contract research.

Malladi is to invest up to $300m over the next three to five years as it attempts to make itself competitive in the oncology, steroids and beta-lactums clinical trials markets.

This commitment was made despite the current financial climate, which is one factor that gives BiotechCorp confidence that global issues are not preventing investments in Malaysia.

Selvam Ramaraj, senior vice president of the Industry Development Division (Healthcare) at BiotechCorp, said: “Even in present circumstances – there is still a good measure of resilience from external shocks which the Malaysian economy still offer in comparison to our neighboring countries​.”

In a report published in 2008 Frost & Sullivan estimates that by 2013, the Malaysian pharma industry will be valued at about $1.8bn, growing at an annual rate of 10.5 per cent.

Related news

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us

Products

View more

Webinars